<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319757</url>
  </required_header>
  <id_info>
    <org_study_id>ACE1702-001</org_study_id>
    <nct_id>NCT04319757</nct_id>
  </id_info>
  <brief_title>ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors</brief_title>
  <official_title>A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acepodia Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acepodia Biotech Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that
      targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate
      the safety and tolerability, pharmacodynamics, and preliminary efficacy of ACE1702 in
      patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II
      starting dose for ACE1702.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 7 through Day 28</time_frame>
    <description>Number of subjects experiencing adverse events, and the frequency and severity of adverse events.
Endpoint for determining the Maximum Tolerated Dose (MTD). If MTD is not identified, the highest dose administered becomes the Maximum Administered Dose (MAD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib/II starting dose for ACE1702</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>The recommended phase Ib/II starting dose based on MTD. If MTD is not reached, then the recommended phase Ib/II dose will be determined based on the MAD, safety data, and pharmacodynamics data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantify NK cell persistence after administering ACE1702</measure>
    <time_frame>Day 21</time_frame>
    <description>Duration of ACE1702 persistence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate immune function after administering ACE1702</measure>
    <time_frame>Day 21</time_frame>
    <description>Measurement of serum cytokine levels, pg/mL (Interferon-γ, TNF-α, IL-2, IL-6, IL-8 and IL-10) at set timepoints</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor response using Response Evaluation Criteria In Solid Tumors Assessment (RECIST) version 1.1</measure>
    <time_frame>Day 35 (+7 day window) of each 6 week cycle, up to 24 months</time_frame>
    <description>Tumor response via radiographic assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Shift in serum tumor marker values (CA-125, CA 19-9, and CEA levels, in applicable tumor types)</measure>
    <time_frame>Day 35 (+7 day window) of each 6 week cycle, up to 24 months</time_frame>
    <description>Tumor response via tumor marker assessments (in applicable tumor types)</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Locally Advanced Solid Tumor</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>HER2-positive Gastric Cancer</condition>
  <condition>HER2-positive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.
Dose Level: 1 Planned number of subjects: 1 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
Dose Level: 2 Planned number of subjects: 1 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
Dose Level: 3 Planned number of subjects: 3 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
Dose Level: 4 Planned number of subjects: 3 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory: HER2-positive Breast/ Gastric Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2 IHC 3+ (HER2-positive), breast or gastric cancer.
Dose Level: established MTD/MAD Planned number of subjects: 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory: HER2-expressing Endometrial Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing, endometrial cancer. HER2 expressing is defined has having HER2 IHC 2+ or above.
Dose Level: established MTD/MAD Planned number of subjects: 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE1702</intervention_name>
    <description>ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously</description>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_label>Exploratory: HER2-expressing Endometrial Cancer</arm_group_label>
    <arm_group_label>Exploratory: HER2-positive Breast/ Gastric Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_label>Exploratory: HER2-expressing Endometrial Cancer</arm_group_label>
    <arm_group_label>Exploratory: HER2-positive Breast/ Gastric Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_label>Exploratory: HER2-expressing Endometrial Cancer</arm_group_label>
    <arm_group_label>Exploratory: HER2-positive Breast/ Gastric Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Subjects must be ≥ 18 years of age

          -  Subject with advanced or metastatic solid tumors that is not amenable to surgical
             resection and is not eligible or has refused other approved therapeutic options that
             have demonstrated clinical benefit.

          -  Histologically confirmed HER2 expression.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1

          -  Measurable or non-measurable evaluable disease according to RECIST 1.1

          -  Adequate hematologic and end-organ function at baseline

          -  Oxygen saturation via pulse oxygenation ≥ 90% at rest on room air

        Exclusion Criteria:

          -  Untreated central nervous system (CNS) metastases

          -  Multiple primary malignancies

          -  Clinically significant cardiovascular disease such as New York Heart Association
             (NYHA) cardiac disease (class III or greater)

          -  Pregnant or lactating female

          -  Serious, uncontrolled medical disorder that, in the opinion of the Investigator, would
             impair the ability of the subject to receive study treatment

          -  History of autoimmune or immune mediated symptomatic disease

          -  Any anti-cancer chemotherapy or targeted small molecule therapy, or experimental
             therapy/device within 4 weeks or 5 half-lives of the drug prior to planned start of
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kurman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acepodia Biotech Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Pan, MPH</last_name>
    <phone>+1-415-839-6787</phone>
    <email>clinical@acepodiabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peninsula Cancer Institute</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NK Cell Therapy</keyword>
  <keyword>Cellular Therapy</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Non-small-cell Lung Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

